Last reviewed · How we verify
JP-1366 and aspirin — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
JP-1366 and aspirin (JP-1366 and aspirin) — Onconic Therapeutics Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| JP-1366 and aspirin TARGET | JP-1366 and aspirin | Onconic Therapeutics Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- JP-1366 and aspirin CI watch — RSS
- JP-1366 and aspirin CI watch — Atom
- JP-1366 and aspirin CI watch — JSON
- JP-1366 and aspirin alone — RSS
Cite this brief
Drug Landscape (2026). JP-1366 and aspirin — Competitive Intelligence Brief. https://druglandscape.com/ci/jp-1366-and-aspirin. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab